Literature DB >> 17162711

Granulosa cell aromatase enzyme activity: effects of follicular fluid from patients with polycystic ovary syndrome, using aromatase conversion and [11C]vorozole-binding assays.

Dmitrijus Kirilovas1, Andrey Chaika, Mats Bergström, Elizabeth Bergström-Petterman, Kjell Carlström, Jelena Nosenko, Svetlana Korniyenko, Anna Yakovets, Iryna Mogilevkina, Tord Naessen.   

Abstract

The local regulation of ovarian aromatase enzyme in polycystic ovary syndrome (PCOS) was studied with aromatase conversion and [11C]vorozole-binding assays to analyze aromatase activity, substrate-enzyme affinity and number of aromatase binding sites in non-cultured human granulosa cells (GC) incubated with different sources and preparations of follicular fluid (FF). Incubation with FF from women stimulated in in vitro fertilization cycles with follicle-stimulating hormone yielded higher conversion activity than with FF from healthy women and PCOS patients, paralleled with higher substrate affinity (lower Kd) than with FF from healthy women. In PCOS women, charcoal-pretreated FF yielded higher conversion, whereas the ether-pretreated FF yielded lower conversion activity, than with untreated PCOS FF. Both preparations of FF yielded higher affinity to substrate (lower Kd values) and the ether-pretreated FF a lower number of binding sites (Bmax). It seems that steroids with the presence of proteins in PCOS FF reduced aromatase conversion activity through decreased substrate affinity, whereas FF preparations devoid of proteins reduced the aromatase conversion activity mainly through blocking of aromatase active sites. Identification of specific agents responsible for this rapid regulation of aromatase function might help to understand normal regulation of the menstrual cycle and supposed imbalances of inhibitors/activators in PCOS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17162711     DOI: 10.1080/09513590601037535

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

Review 1.  Follicular Fluid: A Powerful Tool for the Understanding and Diagnosis of Polycystic Ovary Syndrome.

Authors:  Ana Teresa Brinca; Ana Cristina Ramalhinho; Ângela Sousa; António Hélio Oliani; Luiza Breitenfeld; Luís A Passarinha; Eugenia Gallardo
Journal:  Biomedicines       Date:  2022-05-27

2.  Reinvestigation of the synthesis and evaluation of [N-methyl-(11)C]vorozole, a radiotracer targeting cytochrome P450 aromatase.

Authors:  Sung Won Kim; Anat Biegon; Zachary E Katsamanis; Carolin W Ehrlich; Jacob M Hooker; Colleen Shea; Lisa Muench; Youwen Xu; Payton King; Pauline Carter; David L Alexoff; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2009-04       Impact factor: 2.408

3.  Immunoexpression of aromatase cytochrome P450 and 17β-hydroxysteroid dehydrogenase in women's ovaries after menopause.

Authors:  Agnieszka Brodowska; Jacek Brodowski; Maria Laszczyńska; Sylwia Słuczanowska-Głąbowska; Bogdan Rumianowski; Iwona Rotter; Andrzej Starczewski; Mariusz Z Ratajczak
Journal:  J Ovarian Res       Date:  2014-05-10       Impact factor: 4.234

4.  The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome.

Authors:  Jie Chen; Shanmei Shen; Yong Tan; Dong Xia; Yanjie Xia; Yunxia Cao; Wenjun Wang; Xiaoke Wu; Hongwei Wang; Long Yi; Qian Gao; Yong Wang
Journal:  J Ovarian Res       Date:  2015-03-22       Impact factor: 4.234

Review 5.  Relationship between Advanced Glycation End Products and Steroidogenesis in PCOS.

Authors:  Deepika Garg; Zaher Merhi
Journal:  Reprod Biol Endocrinol       Date:  2016-10-21       Impact factor: 5.211

Review 6.  Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies.

Authors:  Stéphanie Chauvin; Joëlle Cohen-Tannoudji; Céline J Guigon
Journal:  Int J Mol Sci       Date:  2022-01-03       Impact factor: 5.923

Review 7.  Endometriosis and polycystic ovary syndrome are diametric disorders.

Authors:  Natalie L Dinsdale; Bernard J Crespi
Journal:  Evol Appl       Date:  2021-05-14       Impact factor: 4.929

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.